Taken together, metabolites of DEHP may be associated with estrogen-dependent diseases such as uterine leiomyoma that result from an increase in aromatase and estradiol levels attributable to dysregulation of PI3K signaling and PPARγ activity. Here, CYP19A1 is linked to uterine corpus leiomyoma.